Department of Clinical Molecular Biology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Head Neck. 2011 Mar;33(3):309-17. doi: 10.1002/hed.21445.
The aim of the current study was to identify the antitumor activity of satraplatin in paired cisplatin (CDDP)-resistant oral squamous cell carcinoma (OSCC) cell line and its parental cell line.
CDDP-resistant (KB-R) cells and parental cells (KB) pair were used. Viability was assessed using the MTT and clonogenic assay. Real-time polymerase chain reaction (PCR), glutathione (GSH) assay, and flow cytometric analysis were used for further assessment.
KB-R cells did not show cross-resistance to satraplatin. The expression status of almost all transporters was upregulated in the KB-R cells. There was no difference in the GSH levels between the KB and KB-R cells. Flow cytometric analysis indicated that with satraplatin the G2/M phase was arrested in the KB-R cells. KB-R cells contain enriched side population cells.
These data suggested that satraplatin has antitumor activity against the CDDP-resistant OSCC cells. The mechanism of cross-resistance to platinum agents seems to be multifactorial.
本研究旨在鉴定萨他铂对配对顺铂（CDDP）耐药口腔鳞状细胞癌（OSCC）细胞系及其亲本细胞系的抗肿瘤活性。
使用 CDDP 耐药（KB-R）细胞和亲本细胞（KB）对。使用 MTT 和集落形成试验评估细胞活力。Real-time PCR、谷胱甘肽（GSH）测定和流式细胞术分析用于进一步评估。
KB-R 细胞对萨他铂无交叉耐药性。几乎所有转运蛋白的表达状态在 KB-R 细胞中上调。KB 和 KB-R 细胞之间的 GSH 水平没有差异。流式细胞术分析表明，萨他铂可使 KB-R 细胞的 G2/M 期停滞。KB-R 细胞含有丰富的侧群细胞。
这些数据表明，萨他铂对 CDDP 耐药的 OSCC 细胞具有抗肿瘤活性。对铂类药物的交叉耐药机制似乎是多因素的。
